NASDAQ · Medical - Instruments & Supplies

Harvard Bioscience, Inc. (HBIO) Stock

$8.24 +1.35% NASDAQ: HBIO Healthcare

Valuation

MetricValue
Price$8.24
Market Cap$37.16M
P/E Ratio-3.59
P/B Ratio5.09
P/S Ratio0.43
EPS (TTM)$-12.80
52-Week High$9.40
52-Week Low$3.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-92.01%
ROA-13.65%
ROCE1.99%
Gross Margin0.00%
Operating Margin-1.15%
Net Margin-11.86%
Debt/Equity5.96
Current Ratio2.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$119.0M$113.0M$112.0M$94.0M$87.0M
Operating Profit$2.0M$-7.0M$2.0M$-6.0M$-1.0M
Net Profit$0$-10.0M$-3.0M$-12.0M$-57.0M
EPS$-0.07$-2.30$-0.80$-2.80$-12.80
Op Margin1.7%-6.1%1.7%-6.6%-0.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$162.0M$145.0M$137.0M$127.0M$80.0M
Total Liabilities$79.0M$73.0M$64.0M$63.0M$66.0M
Cash$8.0M$5.0M$4.0M$4.0M$9.0M
Borrowings$57.0M$54.0M$43.0M$44.0M$44.0M

Latest News

Sidoti Events, LLC's May Micro-Cap Virtual Conference ACCESS Newswire · May 20, 2026 Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ... GuruFocus.com · May 12, 2026 Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary Moby · May 12, 2026 HBIO Q1 2026 Earnings Transcript Motley Fool · May 12, 2026 Harvard Bioscience: Q1 Earnings Snapshot Associated Press · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$1.0M$1.0M$14.0M$1.0M$7.0M
Investing Cash Flow$-3.0M$-3.0M$-4.0M$-5.0M$-3.0M
Financing Cash Flow$-4.0M$-1.0M$-2.0M$0$0
Net Cash Flow$0$-3.0M$0$0$5.0M
Free Cash Flow$0$0$12.0M$-2.0M$6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA-80.21
FCF Yield-3.75%
Quick Ratio0.98
Interest Coverage0.30
Return 1Y50.75%
Return 3Y-88.96%
Return 5Y-92.03%

Ownership

Insiders Held9.48%
Institutions Held41.46%
Institutions Float Held45.80%
Institutional HolderSharesReport Date
Weber Capital Management LLC /ADV320,0372026-03-31
Acadian Asset Management. LLC179,6142026-03-31
Vanguard Capital Management LLC163,3132026-03-31
Corsair Capital Management, L.P.124,8102026-03-31
Meros Investment Management, Lp118,5222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is led by CEO John Duke, publicly traded since 2001.

Harvard Bioscience, Inc. (HBIO) stock trades at $8.24 with a market capitalization of $37.16M. The stock is valued at a price-to-earnings (P/E) ratio of -3.59, price-to-book of 5.09, price-to-sales of 0.43. Over the past 52 weeks the stock has ranged between $3.76 and $9.40, and currently trades 12.3% below its 52-week high.

On profitability, Harvard Bioscience, Inc. generates a return on equity (ROE) of -92.01%, return on capital employed of 1.99%, an operating margin of -1.15%, a net profit margin of -11.86%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides